WGO Graded Evidence: Osteoporosis

Level: Other Reading: 24 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Prevention and treatment of osteoporosis in inflammatory bowel disease. GR Lichtenstein, BE Sands, M Pazianas, Inflamm Bowel Dis. 2006 Aug:797-813
	Analysis of risk factors for low bone mineral density in inflammatory bowel disease. P Frei, M Fried, V Hungerbuhler, C Rammert, V Rousson, GA Kullak-Ublick, Digestion. 2006:40-6
	Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. A Kornbluth, M Hayes, S Feldman, M Hunt, E Fried-Boxt, S Lichtiger, P Legnani, J George, J Young, Am J Gastroenterol. 2006 Jul:1546-50
	Guidelines do help change behavior in the management of osteoporosis by gastroenterologists. S Kane, D Reddy, Am J Gastroenterol. 2006 Aug:1841-4
	Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. PC Stokkers, M Deley, M Van Der Spek, HJ Verberne, SJ Van Deventer, DW Hommes, Scand J Gastroenterol. 2006 Feb:200-4
	Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. F Walther, C Fusch, M Radke, S Beckert, A Findeisen, J Pediatr Gastroenterol Nutr. 2006 Jul:42-51
	Bone quantitative ultrasound and bone mineral density in children with celiac disease. C Hartman, B Hino, A Lerner, O Eshach-Adiv, D Berkowitz, R Shaoul, A Pacht, E Rozenthal, A Tamir, H Shamaly, R Shamir, J Pediatr Gastroenterol Nutr. 2004 Nov:504-10
	The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. AR Moschen, A Kaser, B Enrich, O Ludwiczek, M Gabriel, P Obrist, AM Wolf, H Tilg, Gut. 2005 Apr:479-87
Supplementary evidence:
	A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. G Pillai, R Gieschke, T Goggin, P Jacqmin, RC Schimmer, JL Steimer, Br J Clin Pharmacol. 2004 Dec:618-31
	Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. SF Ahmed, IA Horrocks, T Patterson, S Zaidi, SC Ling, P McGrogan, LT Weaver, J Pediatr Gastroenterol Nutr. 2004 Mar:276-80
	Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. JS Siffiledeen, RN Fedorak, K Siminoski, H Jen, E Vaudan, N Abraham, H Seinhart, G Greenberg, Inflamm Bowel Dis. 2004 May:220-8
	Case-finding for adult celiac disease in patients with reduced bone mineral density. DS Sanders, D Patel, FB Khan, RH Westbrook, CV Webber, A Milford-Ward, EV McCloskey, Dig Dis Sci. 2005 Mar:587-92
	Celiac disease in patients with an affected member, type 1 diabetes, iron-deficiency, or osteoporosis? JA Murray, Gastroenterology. 2005 Apr:S52-6
	Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. BM Ryan, MG Russel, L Schurgers, M Wichers, J Sijbrandij, RW Stockbrugger, E Schoon, Aliment Pharmacol Ther. 2004 Oct 15:851-7
	Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. JR Boulton-Jones, RM Fenn, J West, RF Logan, SD Ryder, Aliment Pharmacol Ther. 2004 Sep 1:551-7
	Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. A Parés, N Guañabens, J Rodés, Eur J Gastroenterol Hepatol. 2005 Mar:311-5
	Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. N Figura, L Gennari, D Merlotti, C Lenzi, S Campagna, B Franci, B Lucani, L Trabalzini, L Bianciardi, C Gonnelli, A Santucci, A Nut, Dig Dis Sci. 2005 May:847-52
	Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. JH Tobias, MR Sasi, R Greenwood, CS Probert, Aliment Pharmacol Ther. 2004 Nov 1:951-7
	Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. N Franchimont, V Putzeys, J Collette, S Vermeire, P Rutgeerts, M De Vos, A Van Gossum, D Franchimont, R Fiasse, P Pelckmans, M Malaise, J Belaiche, E Louis, Aliment Pharmacol Ther. 2004 Sep 15:607-14
	Review article: Osteoporosis and inflammatory bowel disease. CN Bernstein, WD Leslie, Aliment Pharmacol Ther. 2004 May 1:941-52
	Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. N Guañabens, A Parés, I Ros, L Caballería, F Pons, S Vidal, A Monegal, P Peris, J Rodés, J Hepatol. 2005 Apr:573-7
	Vitamin A intake and osteoporosis: a clinical review. C Crandall, J Womens Health (Larchmt). 2004 Oct:939-53
	Vitamin K status in patients with Crohn's disease and relationship to bone turnover. P Duggan, M O'Brien, M Kiely, J McCarthy, F Shanahan, KD Cashman, Am J Gastroenterol. 2004 Nov:2178-85
	Which is the better choice, estrogen or SERMs in postmenopausal women? M Shintani, Clin Calcium. 2004 Oct:105-10